Summary
Doxorubicin (DXR) incorporated into biodegradable acrylate nanoparticles such as polyisohexylcyanoacrylate (PIHCA) has been shown to increase DXR cytotoxicity and reduce cardiotoxicity by modifying tissue distribution in preclinical studies. We have conducted a phase I clinical trial of DXR-PIHCA in 21 patients with refractory solid tumors (10 male, 11 female, median age: 53 years, median PS: 1, prior free-DXR therapy: 7 patients). A total of 32 courses at 28 day intervals were administered at 6 dose levels (15, 30, 45, 60, 75 and 90 mg/m2). The drug was given as a 10 minute IV infusion on day 1 to the first 5 patients: 2 of them presented a grade 2 allergic reaction (W.H.O. criteria) during infusion, which was rapidly reversible once drug administration was discontinued. Subsequently, in the other 16 patients, the administration was modified to a 60 minute i.v. perfusion diluted in 250 cc of Dextrose 5%: only 1 patient presented the same allergic reaction. Grade 2 fever and vomiting occurred in 9 patients and 7 patients respectively during the first 24 h after treatment. There was no cardiac toxicity among the 18 evaluable patients. Grade 3 or 4 hematologic toxicity occurred at the 75 and 90 mg/m2 dose level. The dose limiting toxicity was neutropenia. The maximum tolerated dose was 90 mg/m2 and the recommended phase II dose was 75 mg/m2. A pharmacokinetic evaluation of DXR-PIHCA was conducted in 3 patients each at a different dose level (60,60 and 75 mg/m2) and was compared with free DXR given to the same patients in the same conditions.
Similar content being viewed by others
References
O'Bryan, R, Luce J, Talley R, Gottlieb J, Baker L, Bonadonna G: Phase II evaluation of adriamycin in human neoplasia. Cancer 32:1–8, 1973
O'Bryan R, Baker L, Gottlieb J, Rivkin S, Balcerzak S, Grumet G, Salmon S, Moon T, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940–1948, 1977
Bristow M, Lopez M, Mason J, Billingham M, Winchester M: Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 50:32–41, 1982
Couvreur P, Roblot-Treupel L, Poupon M, Brasseur F, Puisieux F: Nanoparticles as microcarriers for anticancer drugs. Ad Drug Delivery Rev 5:209–230, 1990
Storm G, Van Hoesel O, Groot G, Kop W, Steerenberg P, Hillen F: A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus continuous infusion or entrapped in liposomes in the Lou/M Wsl rat. Cancer Chemother Pharmacol 24:341–348, 1989
Rahman A, Treat J, Roh JK, Potkul L, Alvord W, Forst D, Wooly P: A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8:1093–1100, 1990
Couvreur P: Polyalkylcyanoacrylate as colloîdal drug carriers. CRC Crit Rev Therapeutic Drug Carrier Systems 6:1–19, 1988
Couvreur P, Roblot-Treupel L, Puisieux F, Fattal E, Andremont A, Chiannilkulchain N, Brasseur F: Improved efficacy and safety by incorporation into minivesicles or miniparticles. In: Breimer DD, Grommelin DJA, Midha KK (ed) Topics in pharmaceutical sciences Elsevier, Amsterdam, 1989, pp 651–659
Couvreur P, Kante B, Grislain L, Roland M, Speiser P: Toxicity of polyalkylcyanoacrylate nanoparticles. II. Doxorubicin-loaded nanoparticles. J Pharm Sci 71:790–792, 1982
Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M: Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles: Cancer Chemother Pharmacol 26:13–18, 1990
Chiannilkulchai N, Driouich Z, Benoit JP, Poradi AL, Couvreur P: Doxorubicin-loaded nanoparticles: Increased efficiency against murine hepatic metastases. Sel Cancer Ther 5(1):1–11, 1989
Chiannilkulchai N, Ammoury N, Caillou B, Devissaguet JPh, Couvreur P: Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother Pharmacol 26:122–126, 1990
Kubiak C, Couvreur P, Manil L, Clausse B: Increased cytotoxicity of nanoparticle-carried adriamycin in vitro and potentiation by verapamil and amiodarone. Biomaterials 10: 553–556, 1989
Jasmin C, Gil-Delgado M, Marino JP, Ecstein E, Descorps-Declere A, Misset JL: Phase I–II constant infusion of adriamycin (doxyrubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients. Ann Oncol 1:189–193, 1990
Baurain R, Deprez-De Campeneere D, Trouet A: Rapid determination of doxorubicin and its fluorescent metabolites by high pressure chromatography. Analytical Biochemistry 94:112–116, 1979
Verdun C, Couvreur P, Vranckx H, Lenaerts V, Roland M: Development of a nanoparticle controlled-release formulation for human use. J Controlled Release 3: 205–211, 1986
World Health Organization: WHO handbook for reporting the results of cancer treatment. WHO offset publication, Geneva, 48, 1979
Ljungström KG, Renck H, Stranolberg K, Hedin H, Richter W, Widerlöv E: Adverse reactions to dextran in Sweden 1970–1979. Acta chir Scand 149:253–262, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kattan, J., Droz, JP., Couvreur, P. et al. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest New Drugs 10, 191–199 (1992). https://doi.org/10.1007/BF00877245
Issue Date:
DOI: https://doi.org/10.1007/BF00877245